Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share for 2Q25, indicating more efficient financial management than initially anticipated. Additionally, the clinical trial of OKI-219 showed promising results, as it was well-tolerated across all dose levels with minimal adverse events reported. This favorable safety profile may enhance the potential market acceptance of OKI-219, positioning OnKure favorably within the competitive landscape of cancer therapeutics.

Bears say

OnKure Therapeutics is projected to incur a substantial full-year net loss of $4.56 per share in 2025, reflecting a minor improvement from a previous estimate of $4.75 per share. The company faces several risks that may negatively impact its financial performance, including potential negative clinical outcomes with its lead asset, OKI-219, and delays in advancing its pipeline candidates. Furthermore, challenges in obtaining timely regulatory approvals and increasing competition in the biopharmaceutical space contribute to a pessimistic outlook for the company's future profitability and stock performance.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.